Minomic relocates HQ to Macquarie Uni Hospital

Minomic International has relocated its Australian scientific headquarters to Macquarie University’s medical precinct as it prepares to commercialise prostate screening technology MiSat ELISA.

The company’s new headquarters is located in the Macquarie University Hospital’s Australian School of Advanced Medicine.

Announcing the move, Minomic said its new location will facilitate collaboration with Australia’s leading life science and clinical experts.

It will also provide the company with optimal access to the patient populations required to pursue final development of MiSat ELISA, a blood or urine test for a proprietary biomarker found only on prostate cancer cells. Minomic aims to apply for a CE Mark for the test later this year.

The relocation will also allow Minomic and Macquarie University scientists to more closely collaborate on developing non-invasive cancer diagnostic tests using Macquarie’s new Super Dot nanocrystal technology.

Under this collaboration, Minomic antibodies will be combined with the Super Dot platform to enable the detection of abnormal cells in body fluids.

“This project marries Minomic’s existing technology on proprietary antibodies with Macquarie’s sophisticated diagnostic technology,” Minomic CIO Dr Brad Walsh said.

“This project will strengthen our company’s existing intellectual property portfolio and ultimately, we anticipate being able to deliver even better, highly sensitive prostate cancer screening technologies to the global market.”